CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 253.35 AUD -0.77%
Market Cap: 122.7B AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is 272.79 AUD. Compared to the current market price of 253.35 AUD, CSL Ltd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
Base Case
272.79 AUD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
98
vs Industry
54
Median 3Y
6.7
Median 5Y
8.4
Industry
7.3
Forward
4.9
More Details
28.3
P/E
P/E
Price to Earnings
28.3
vs History
98
vs Industry
4
Median 3Y
38.2
Median 5Y
39.2
Industry
21.6
Forward
24.5
More Details
26.4
P/OCF
P/OCF
Price to OCF
26.4
vs History
87
vs Industry
5
Median 3Y
33.5
Median 5Y
33.5
Industry
19.8
More Details
55
P/FCFE
P/FCFE
Price to FCFE
55
vs History
60
vs Industry
1
Median 3Y
55.3
Median 5Y
71.1
Industry
24.9
More Details
4.2
P/B
P/B
Price to Book Value
4.2
vs History
98
vs Industry
15
Median 3Y
5.6
Median 5Y
6.4
Industry
2.4
More Details
5.6
EV/S
EV/S
Enterprise Value to Sales
5.6
vs History
98
vs Industry
44
Median 3Y
7.3
Median 5Y
8.8
Industry
7.4
Forward
5.4
More Details
10.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.9
vs History
98
vs Industry
29
Median 3Y
14.2
Median 5Y
16.1
Industry
9.3
More Details
17.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.4
vs History
98
vs Industry
5
Median 3Y
22.9
Median 5Y
25
Industry
3.9
Forward
15.8
More Details
21.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
21.8
vs History
98
vs Industry
4
Median 3Y
28.5
Median 5Y
29.8
Industry
3.7
Forward
18.9
More Details
29
EV/OCF
EV/OCF
Enterprise Value to OCF
29
vs History
80
vs Industry
4
Median 3Y
35.8
Median 5Y
35.8
Industry
4.9
More Details
45.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
45.9
vs History
88
vs Industry
2
Median 3Y
81.9
Median 5Y
80.5
Industry
3.2
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
98
vs Industry
39
Median 3Y
3.2
Median 5Y
5.6
Industry
4.3
More Details

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
123.6B AUD 5.1 28.3 17.4 21.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 547 712.8 -173 705.9 -210 934.3 -208 527.2
US
Abbvie Inc
NYSE:ABBV
374.2B USD 6.6 88.3 17.2 26
US
Amgen Inc
NASDAQ:AMGN
169.1B USD 5.1 41.4 16.6 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
131.5B USD 4.6 273.9 10.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.9B USD 11.9 -244.5 26.8 28.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 927.6 -491.9 -535.6 -521.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.6B USD 5.1 16.5 10.8 12.1
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.3 -55.3
NL
argenx SE
XBRU:ARGX
34B EUR 16.8 44.3 327.8 -2 414.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.8B USD 14.6 -117.9 -258.8 -175.9
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 322 702.6
5.1
7%
0.7
FR
Pharnext SCA
OTC:PNEXF
36 547 712.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.9
10%
1.2
US
E
Epizyme Inc
F:EPE
1 927.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.6
28%
0.5
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 82.1
28.3
16%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 705.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.3
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.4
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
273.9
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
44.3
19%
2.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -117.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 61.1
17.4
12%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
NL
argenx SE
XBRU:ARGX
327.8
168%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -258.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 21.8
21.8
14%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 414.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -175.9 N/A N/A

See Also

Summary
CSL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CSL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CSL stock valuation using valuation multiples.
Wall Street Estimates
CSL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CSL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 240,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.